Celldex Therapeutics, Inc. (NASDAQ:CLDX) registered a -3.85% decrease, still its new closing price is 14.04% up from the company’s 1 year high of 9.81.It posted -3.27% losses in previous 5 sessions and is now the subject of 4 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 9 stock analysts following this company have an average price target at $7.38, with individual PT in the $3.00-$12.00 range. The shares moved at $3.25, implying that brokerage firms see shares losing about -60.84% in twelve months time.
Celldex Therapeutics, Inc. (CLDX) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -8.19% fall year to date. A Executive VP & CSO at Celldex Therapeutics, Inc. (CLDX) acquired shares in a transaction closed on Friday September 02, 2016. KELER TIBOR bought 3,000 shares in the company at $3.32 each and collected $9,001 in proceeds. KELER TIBOR now owns 18,868 shares in the company after this transaction. A Sr. VP & CFO in the company, CATLIN AVERY W, disclosed a transaction on Monday November 23, 2015 that ended up generating $450,000 from the sale of 25,000 shares at $18 per share.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Upcoming Results on Tap
Celldex Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.31 in that period. Sales during the quarter are predicted to arrive at $1.
Earnings surprise history: Last quarter, the company posted approximately $2.22 million in revenue and EPS of $-0.29. The mean forecast was for $1 and $-0.33 a share, respectively. One quarter earlier, revenue for the stock was at $1.39 million, with earnings at $-0.32/share.
Celldex Therapeutics, Inc. (CLDX) Brokerage Update
Celldex Therapeutics, Inc. (CLDX) is in Jefferies’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Jefferies, according to news reported on Tuesday March 08, 2016.Another important research note was issued by Leerink Partners on Monday March 07, 2016.The firm downgraded CLDX to Mkt Perform from Outperform. Over the last six months and over the last three months, the shares of Celldex Therapeutics, Inc. (CLDX), have changed -29.65% and 0.62%, respectively.